BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 22480803)

  • 1. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy.
    Yarnitsky D; Granot M; Nahman-Averbuch H; Khamaisi M; Granovsky Y
    Pain; 2012 Jun; 153(6):1193-1198. PubMed ID: 22480803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.
    Wernicke JF; Pritchett YL; D'Souza DN; Waninger A; Tran P; Iyengar S; Raskin J
    Neurology; 2006 Oct; 67(8):1411-20. PubMed ID: 17060567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duloxetine for treating painful neuropathy or chronic pain.
    Lunn MP; Hughes RA; Wiffen PJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007115. PubMed ID: 19821395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duloxetine vs. placebo in patients with painful diabetic neuropathy.
    Goldstein DJ; Lu Y; Detke MJ; Lee TC; Iyengar S
    Pain; 2005 Jul; 116(1-2):109-18. PubMed ID: 15927394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.
    Raskin J; Pritchett YL; Wang F; D'Souza DN; Waninger AL; Iyengar S; Wernicke JF
    Pain Med; 2005; 6(5):346-56. PubMed ID: 16266355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo.
    Gao Y; Guo X; Han P; Li Q; Yang G; Qu S; Yue L; Wang CN; Skljarevski V; Dueñas H; Raskin J; Gu L
    Int J Clin Pract; 2015 Sep; 69(9):957-66. PubMed ID: 25939897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duloxetine for the management of diabetic peripheral neuropathic pain: response profile.
    Pritchett YL; McCarberg BH; Watkin JG; Robinson MJ
    Pain Med; 2007; 8(5):397-409. PubMed ID: 17661853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can topical duloxetine be used for neuropathic pain?
    Hsu YC; Tzeng NS
    Med Hypotheses; 2014 Feb; 82(2):175-6. PubMed ID: 24332447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between average daily dose, medication adherence, and health-care costs among diabetic peripheral neuropathic pain patients initiated on duloxetine therapy.
    Chen SY; Wu N; Boulanger L; Fraser KA; Zhao Y
    Pain Pract; 2010; 10(6):530-9. PubMed ID: 20412505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACP Journal Club. Review: In neuropathy, fibromyalgia, or chronic pain, duloxetine reduces pain but increases adverse events.
    Engel CC
    Ann Intern Med; 2014 Apr; 160(8):JC12. PubMed ID: 24733217
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain.
    Wu EQ; Birnbaum HG; Mareva MN; Le TK; Robinson RL; Rosen A; Gelwicks S
    J Pain; 2006 Jun; 7(6):399-407. PubMed ID: 16750796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies.
    Kajdasz DK; Iyengar S; Desaiah D; Backonja MM; Farrar JT; Fishbain DA; Jensen TS; Rowbotham MC; Sang CN; Ziegler D; McQuay HJ
    Clin Ther; 2007; 29 Suppl():2536-46. PubMed ID: 18164920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.
    Smith EM; Pang H; Cirrincione C; Fleishman S; Paskett ED; Ahles T; Bressler LR; Fadul CE; Knox C; Le-Lindqwister N; Gilman PB; Shapiro CL;
    JAMA; 2013 Apr; 309(13):1359-67. PubMed ID: 23549581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duloxetine and pregabalin: high-dose monotherapy or their combination? The "COMBO-DN study"--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain.
    Tesfaye S; Wilhelm S; Lledo A; Schacht A; Tölle T; Bouhassira D; Cruccu G; Skljarevski V; Freynhagen R
    Pain; 2013 Dec; 154(12):2616-2625. PubMed ID: 23732189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine reduces morphine requirements after knee replacement surgery.
    Ho KY; Tay W; Yeo MC; Liu H; Yeo SJ; Chia SL; Lo NN
    Br J Anaesth; 2010 Sep; 105(3):371-6. PubMed ID: 20573635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects.
    Prescrire Int; 2006 Oct; 15(85):168-72. PubMed ID: 17121211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duloxetine ameliorates the impairment of diffuse noxious inhibitory control in rat models of peripheral neuropathic pain and knee osteoarthritis pain.
    Yoneda S; Kasai E; Matsuo M; Tamano R; Sakurai Y; Asaki T; Fujita M
    Neurosci Lett; 2020 Jun; 729():134990. PubMed ID: 32315711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study.
    Raskin J; Wang F; Pritchett YL; Goldstein DJ
    Pain Med; 2006; 7(5):373-85. PubMed ID: 17014595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy.
    Majdinasab N; Kaveyani H; Azizi M
    Drug Des Devel Ther; 2019; 13():1985-1992. PubMed ID: 31354243
    [No Abstract]   [Full Text] [Related]  

  • 20. Review of duloxetine in the management of diabetic peripheral neuropathic pain.
    Smith T; Nicholson RA
    Vasc Health Risk Manag; 2007; 3(6):833-44. PubMed ID: 18200804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.